fda approve interim analysis

Sunshine Heart Receives FDA Approval for Interim Analysis of U.S. Pivotal Trial of C-Pulse(R) Heart Assist System
Sunshine Heart, Inc. 1 hour ago GlobeNewswire

• 
• 
• 
• 

EDEN PRAIRIE, Minn., Feb. 25, 2015 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc. (SSH) today announced it has received unconditional approval from the FDA to conduct an interim analysis of COUNTER HF, the Company's U.S. pivotal study. The COUNTER HF study is a prospective, randomized, multi-center, controlled study that evaluates the safety and efficacy of the C-Pulse system for the treatment of NYHA Class III and ambulatory Class IV heart failure. Integral to the COUNTER HF study is the assessment of C-Pulse's unique balloon counterpulsation treatment designed to improve heart function and reduce re-hospitalizations due to worsening heart failure.
"Today's announcement is a significant achievement for the company as it offers the potential to dramatically reduce the development timeline for this important solution for heart failure. The FDA decision to approve this interim analysis is not only unconditional but also arrives earlier than the originally anticipated timeframe of end Q1 2015. We are grateful for the FDA's rapid response to our submission and look forward to working with the Agency through the balance of the COUNTER HF study and on the development of the next generation, fully implantable C-Pulse system," commented Dave Rosa, President and Chief Executive Officer of Sunshine Heart.
A key potential benefit of conducting the analysis is the prospect of reducing the overall duration of the study should COUNTER HF meet the higher statistical threshold of the interim analysis. The study is a prospective, randomized, multi-center clinical trial. It is being conducted by heart failure and cardiac surgeon specialists in the United States. It is expected to randomize 388 patients in up to 40 clinical sites. The purpose of the study is to determine whether the C-Pulse System is a safe and effective treatment for heart failure patients who meet the following key study qualifications:

• NYHA Class III or early Class IV heart failure*;
• Ejection fraction <= 35% (measure of how well the heart pumps blood);
• Taking appropriate heart failure medications as prescribed by doctor; and
• Have been evaluated for cardiac resynchronization therapy with or without defibrillation (CRT, CRT-D) or implantable cardioverter defibrillator (ICD) therapy.

*New York Heart Class (NYHA) Class III or early Class IV: Very limited in daily activities or unable to do activities without discomfort. Become tired, short of breath, and have heart palpitations during physical activity. Note: Other qualifications apply and study doctors will determine who is eligible for the study.
Individuals who are interested in learning more about the trial and if they might qualify for the study can visit www.HFClinicalStudy.com or call 1-888-978-8391.
About the C-Pulse(R) Heart Assist System
The C-Pulse Heart Assist System, or C-Pulse System, an investigational device in the United States, Canada and countries that do not recognize the CE mark approval, utilizes the scientific principles of intra-aortic balloon counter-pulsation applied in an extra-aortic approach to assist the left ventricle by reducing the workload required to pump blood throughout the body, while increasing blood flow to the coronary arteries. Combined, these potential benefits may help sustain the patient's current condition or, in some cases, reverse the heart failure process, thereby potentially preventing the need for later-stage heart failure devices, such as left ventricular assist devices (LVADs), artificial hearts or transplants. It may also provide relief from the symptoms of Class III and ambulatory Class IV heart failure and improve quality of life and cardiac function. Based on the results from our feasibility study, we also believe that some patients treated with our C-Pulse System may be able to stop using the device due to sustained improvement in their conditions as a result of the therapy.
Caution: Investigational device, limited by Federal (or United States) Law to Investigational use.
About Sunshine(R) Heart
Sunshine Heart, Inc. (SSH) is an early-stage medical device company focused on developing, manufacturing and commercializing the C-Pulse System for treatment of Class III and ambulatory Class IV heart failure. Sunshine Heart has completed an approved U.S. Food and Drug Administration (FDA) feasibility clinical study of the C-Pulse System and presented the results in November 2011. In March 2012, the FDA notified the Company that it could move forward with an investigational device exemption (IDE) application. Sunshine Heart received unconditional approval from the FDA in November 2012 to initiate its pivotal study. In July 2012, Sunshine Heart received CE Mark approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware corporation headquartered in Minneapolis with wholly owned subsidiaries in Australia and Ireland. The Company has been listed on the NASDAQ Capital Market since February 2012.
Forward-Looking Statements
Certain statements in this release are forward-looking statements that are based on management's beliefs, assumptions, expectations, and information currently available to management. All statements that address future operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including, without limitation, our expectations with respect to future clinical study activities and results including patient enrollment in studies. These forward-looking statements are subject to numerous risks and uncertainties, including, without limitation, the possibility that our clinical studies do not meet their enrollment goals, meet their endpoints or otherwise fail, that regulatory authorities do not accept our application or approve the marketing of the C-Pulse System, the possibility that we may be unable to raise the funds necessary for the development and commercialization of our products, that we may not be able to commercialize our products successfully in the EU and the other risk factors described under the caption "Risk Factors" and elsewhere in our filings with the U.S. Securities and Exchange Commission. You should not place undue reliance on forward-looking statements because they speak only as of the date when made and may turn out to be inaccurate. We do not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. We may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

mce-anchor
View photo
.


Contact:
For further information, please contact:
Investor:
Candice Knoll
Blueprint Life Science Group
T: +1-415-375-3340 Ext. 105
Claudia Drayton
Chief Financial Officer
Sunshine Heart, Inc.
T: +1-952-345-4200
Media:
David Schull
Russo Partners
T: +1-212-845-4271
Christopher Hippolyte
Russo Partners
T: + 1-646-942-5634
Rates

View Comments (0)
Share this

• 
• 
• 
• 

Recommended for You

• 
  5 Things You Do Every Day That Can Improve Your Credit
  
  Among all the strategies out there for improving your credit standing, it's important to take note of the things that are easy. Some of the best ways you can help your credit are so ingrained in your day-to-day routine, you're probably working on your credit without really thinking about it. The…
  Huffington Post
  

• 
  Magnificent mansions with tales to tell
  
  Visit the great country estates of Britain's famous figures, from Elizabethan lords to modern day Dukes, and even Winston Churchill.
  Visit BritainSponsored
  
• 
  Splunk’s (SPLK) Value Is in the Clouds; Investors Should Take Profits Now
  
  The cloud and big-data markets are driving profits higher for many software companies, but data analytics specialist Splunk (SPLK - Get Report) has struggled to grow its bottom line. While its revenue is growing at impressive rates, Splunk's valuation remains a concern. The stock is trading at…
  The Street
  SPLK $66.44 -3.15%
  

Waffle House becomes an unlikely competitor to FedEx and UPS

The US diner chain today announced a partnership with Roadie, a startup that aims to become the "Uber of package delivery." The app, which launched last month, lets travelers earn money by delivering packages to locations along their routes. Waffle House will also offer a free waffle and drink to…
The Verge
FDX $177.80 -0.28%

Play Video
Blodget: We have enough jobs, they just need to pay better

Jobs die out. Technology creates new ones. But are there enough good paying jobs to replace the ones that are disappearing? It's an old question sparking new debate.
Yahoo Finance


Religious groups back Muslim woman in U.S. high court scarf case

By Lawrence Hurley WASHINGTON (Reuters) - A Muslim woman denied a sales job at an Abercrombie & Fitch Co clothing store in Oklahoma because she wears a head scarf has won the support of Christians, Jews, Sikhs and fellow Muslims as the U.S. Supreme Court prepares to hear her case. Various religious…
Reuters
ANF $25.66 -0.12%

• 
  Find your Flavor at Dubai Food Festival 2015
  
  Dubai Food Festival promotes the diversity, creativity and multicultural nature of Dubai’s culinary offering!
  Dubai Food FestivalSponsored
  
• 
  Get money back at the grocery store with these 11 apps
  
  Anyone who has visited a grocery store lately knows that food is only getting more expensive. Fortunately, a new generation of digital grocery apps give consumers a high-tech way to save. All you have to do is purchase an eligible product and take a picture of the receipt. Some apps require another…
  Business Insider
  

The Easy Oil Is Gone, So Where Do We Look Now?

In 2008, Canadian economist Jeff Rubin stunned the oil market with a bold prediction: With the world economy growing at 5 percent a year, oil demand would grow with it, outpacing supply, thus lifting the oil price from $147 to over $200 a barrel. The former chief economist at CIBC World Markets was…
247wallst.com

When Is It OK to Call In Sick?

What if you don't have paid sick leave? What should managers do to encourage good sick leave practices among employees?
U.S.News & World Report

Jim Cramer's Top Stock Picks: AAPL DOW VRX XEC FTK

Cramer says Dow Chemical has become a cash machine while Valeant Pharmaceuticals' growth is mesmerizing.
TheStreet.com

• 
  Experience EPIC Value.
  
  The New Touareg. Epic value, like never before. Visit your local dealer to book a test drive.
  Volkswagen Middle EastSponsored
  
• 5 Tips To Save $1 Million For Retirement
  
  One million bucks is a lot of money. It certainly is impressive if you're one of the few who has saved that much for retirement — looking at your statement and seeing all those zeros.And even financial planners who say you might need more for your retirement can't argue that it is an impressive…
  Huffington Post
  

This Monthly Dividend Strategy Has Outpaced Realty Income (EXR, NNN, O, WPC)

Your bills come once a month, why shouldn't your dividend check? - Dave Koppenheffer - Financials
The Motley Fool

Why Coca Cola Co. Just Gave Dividend Investors an 8% Raise

The beverage king last week hiked its dividend payment for 2015.
Motley Fool
KO $42.13 0.67%

U.S. firm Raytheon agrees to equip UAE armoured vehicles with rockets

U.S. weapons maker Raytheon Co agreed with the United Arab Emirates on Monday to equip the oil-rich Gulf country's armoured vehicles with Talon laser-guided rockets, a company official told Reuters. "It's a capability with a very meaningful demand from the community ... not just for UAE's needs but…
Reuters
RTN $110.19 0.48%

• 
  Stand out in a Fusion
  
  A car that keeps you in your lane.
  FordSponsored
  
• Transocean shares poised for big move after results
  
  Transocean Ltd shares are expected to move about 8 percent in either direction following its earnings results on Wednesday, options data showed, but positioning among traders suggests some worry. The cost of a weekly Transocean straddle, where an investor buys an at-the-money put option and a…
  Reuters
  RIG $15.95 -1.91%
  

Dear Hiring Manager: All The Disability-Related Skills I Can't Put On My Resume

Dear Hiring Manager,By now, you've probably skimmed over my meticulously-worded resume, and maybe you've even made up your mind as to whether I'm as qualified as the nearly identical resumes of my fellow recent graduates. You may have even Googled me and seen the many blogs I have written about my…
Huffington Post

Young money: A case for renters insurance

Renters insurance is constantly overlooked, as 60% of renters do not have it. CNBC's Landon Dowdy zeros in on that in the latest episode of Young Money.
CNBC Videos

Key points of the Baker Hughes and Halliburton merger

The Baker Hughes and Halliburton merger is a cash and stock transaction.
Market Realist
BHI $63.03 0.17%

• 
  Save 75% on Leading Brands at MarkaVIP.com
  
  Love Fashion? Check out MarkaVIP's latest flash sales including sunglasses from Gucci. Join online today so you never miss another sale.
  MarkaVIPSponsored
  
• Alibaba Shares Nearing All-Time Low
  
  Joel Elconin is the co-host of Benzinga's #PreMarket Prep , a daily trading idea radio show. Alibaba Group Holding Ltd (NYSE: BABA ) shares were trading lower by $1.37 (1.5 percent) at $84.10 in Tuesday's ...
  Benzinga
  

American Capital calls spike again

The bulls were piling into American Capital yesterday for the second session in a row ahead of its earnings report this afternoon. optionMONSTER's Heat Seeker monitoring program detected the purchase of ...
optionMONSTER
ACAS $14.90 0.13%

First Energy and Duke Energy among top losers in power utilities

Among power utilities, First Energy (FE) saw the biggest drop in share prices for the week ended February 20, 2015.
Market Realist
DUK $79.85 0.74%



Press Releases

• Sunshine Heart to Present at the Cowen and Company 35th Annual Health Care Conference on March 4, 2015
• Sunshine Heart, Inc. Secures Up to $10 Million in Growth Capital From Silicon Valley Bank
• Sunshine Heart Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

More Press Release for Sunshine Heart Inc.
Related Quotes

• SSH5.41+0.93%

Sunshine Heart Inc.